悦康药业：子公司YKYY032注射液获国家药品监督管理局和FDA临床试验批准

Core Viewpoint - Yuyuan Pharmaceutical announced that its subsidiaries, Beijing Yuyuan Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd., have received approval from the National Medical Products Administration for the clinical trial of YKYY032 injection for the treatment of hyperlipoproteinemia(a) [1] Group 1 - The approval from the National Medical Products Administration includes the issuance of a "Drug Clinical Trial Approval Notice" for YKYY032 injection [1] - Yuyuan Kechuang has also received a letter of consent from the U.S. Food and Drug Administration to conduct clinical trials for YKYY032 injection for the same indication [1]